10-Q: Verastem Q2: AVMAPKI FAKZYNJA Launch Drives Revenue

Verastem, Inc. reports Q2 2025 financial results, highlighting initial product revenue from its newly approved AVMAPKI FAKZYNJA CO-PACK and progress across its oncology pipeline.

Summary

• FDA approved AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) on May 8, 2025, for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy.
• Achieved net product revenue of $2.1 million in the first six weeks of AVMAPKI FAKZYNJA CO-PACK launch (May 8 June 30, 2025).
• Total revenue for the three months ended June 30, 2025, was $2.1 million, a decrease from $10.0 million in the same period of 2024, primarily due to a $10.0 million COPIKTRA sales milestone received in Q2 2024 not recurring.
• Net loss for the three months ended June 30, 2025, was $25.9 million, compared to a net loss of $8.3 million for the same period in 2024.
• Research and development expenses increased by $6.7 million (37%) to $24.8 million in Q2 2025, driven by higher contract research organization (CRO) costs, investigator fees, personnel costs, and clinical supply costs.
• Selling, general and administrative expenses increased by $10.5 million (102%) to $20.7 million in Q2 2025, primarily due to consulting and professional fees related to the AVMAPKI FAKZYNJA CO-PACK launch and increased personnel costs.
• Cash, cash equivalents, and investments totaled $164.3 million as of June 30, 2025, with an expected cash runway into the second half of 2026.
• The first patient was dosed in the U.S. Phase 1/2a clinical trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced KRAS G12D mutant solid tumors in June 2025.
• Positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) showed an 83% confirmed Objective Response Rate (ORR) in the dose level 1 cohort (10 out of 12 patients).
• Enrollment for the Phase 3 RAMP 301 confirmatory trial for recurrent LGSOC is nearing completion, with a pre-planned Interim Analysis by an Independent Data Monitoring Committee (IDMC) expected in Q4 2025.

Sentiment

Score: 5

Explanation: While the FDA approval and initial product revenue are significant positives, the substantial increase in net loss, the explicit 'going concern' warning, and the reliance on future capital raises or milestones temper the overall sentiment. The pipeline progress is promising but still in development stages, creating a balanced risk-reward profile.

Positives

• FDA approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025, for KRAS-mutated recurrent LGSOC, approximately two months ahead of its PDUFA action date.
• Achieved $2.1 million in net product revenue in the first six weeks of AVMAPKI FAKZYNJA CO-PACK launch, demonstrating initial commercial traction.
• AVMAPKI FAKZYNJA CO-PACK was included in the National Comprehensive Cancer Network (NCCN) Guidelines as a Category 2A recommendation for KRAS-mutated recurrent LGSOC, aligning with the FDA-approved indication.
• The first patient was dosed in the U.S. Phase 1/2a trial for VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, marking progress in a key pipeline program.
• VS-7375 received Fast Track Designation from the FDA for first-line and previously treated KRAS G12D-mutated locally advanced or metastatic PDAC, potentially accelerating its development and review.
• Positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial in first-line metastatic PDAC, with a confirmed Objective Response Rate (ORR) of 83% (10/12 patients) in the selected recommended Phase 2 dose (RP2D) cohort, indicating strong clinical activity.
• The RAMP 205 study met pre-defined criteria to advance beyond the first stage of the expansion study, progressing its development.
• Enrollment in the Phase 3 RAMP 301 confirmatory trial for recurrent LGSOC is nearing completion, indicating timely progress towards potential full approval and expanded indications.
• Orphan Drug Designation was granted for avutometinib plus defactinib for the treatment of ovarian cancer by the European Commission, which may provide market exclusivity and development incentives.
• Ended Q2 2025 with $164.3 million in cash, cash equivalents, and investments, providing an expected cash runway into the second half of 2026, bolstered by recent financing activities.

Negatives

• Net loss significantly increased to $25.9 million in Q2 2025 from $8.3 million in Q2 2024, indicating a worsening financial performance.
• Total revenue decreased to $2.1 million in Q2 2025 from $10.0 million in Q2 2024, primarily due to the absence of a one-time $10.0 million COPIKTRA sales milestone payment received in the prior year.
• Total operating expenses rose by 62% to $45.9 million in Q2 2025, driven by substantial increases in both research and development ($6.7 million increase) and selling, general and administrative expenses ($10.5 million increase).
• The company explicitly states "substantial doubt about our ability to continue as a going concern for 12 months after the date the condensed consolidated financial statements are issued," highlighting significant financial uncertainty.
• Incurred a loss on debt extinguishment of $1.8 million in Q2 2025 related to the early repayment of the Oxford Loan Agreement.

Risks

• Substantial doubt exists about the ability to continue as a going concern for 12 months after the financial statements are issued, due to anticipated operating losses and ongoing costs.
• Failure to obtain additional capital or generate sufficient revenue from commercialization activities may prevent the completion of planned preclinical studies, clinical trials, and regulatory approvals.
• Uncertainties inherent in research and development, such as the possibility of negative or unexpected results of clinical trials.
• Uncertainty regarding the occurrence or timing of applications for product candidates that may be filed with regulatory authorities in any jurisdictions.
• Uncertainty whether and when regulatory authorities in any jurisdictions may approve applications for product candidates and, if approved, whether they will be commercially successful.
• The impact of current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services, could prevent or delay marketing approval, restrict post-approval activities, and affect pricing.
• Increased scrutiny by the U.S. Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject the company to more stringent product labeling and post-marketing testing and other requirements.
• The U.S. Supreme Court's June 2024 decision in Loper Bright Enterprises v. Raimondo could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, leading to increased regulatory uncertainty and inconsistent judicial interpretations.
• Uncertainty regarding potential regulatory developments following the change in the U.S. presidential administration (Trump Administration) that may adversely affect the business or create a more challenging and costly environment for development and commercialization.
• Potential for reductions in the FDA's workforce under the current administration, which may lead to disruptions and delays in the FDA's review and oversight of product candidates.
• Failure to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S. could result in additional reimbursement requirements, penalties, sanctions, and fines.
• Competitive developments affecting product candidates may result in others developing or commercializing products before or more successfully, leading to reduced market share or potential.
• Data may not be available when expected, or enrollment of clinical trials may take longer than expected.
• Preliminary or interim data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials.
• Marketed products and product candidates may cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles.
• Inability to successfully validate, develop, and obtain regulatory approval for companion diagnostic tests for product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so.
• Inability to confirm the results from the RAMP 201 study or expand the approved indication for AVMAPKI FAKZYNJA CO-PACK.
• Product candidates may experience manufacturing or supply interruptions or failures.
• Reliance on third-party contract research organizations, contract manufacturing organizations, clinical sites, or contractors who may fail to fully perform.
• Inability to establish new or expand on existing collaborations or partnerships, including with respect to in-licensing of product candidates, on favorable terms, or at all.
• Inability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing, or otherwise.
• May not pursue or submit regulatory filings for product candidates.
• Product candidates will not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Future Outlook

The company anticipates operating losses will continue for the foreseeable future as it incurs costs to execute its strategic plan, including research and development and commercial activities. It expects to finance operations with existing cash, future net product revenues, potential future milestones and royalties from the Secura APA, the Note Purchase Agreement, or other strategic financing opportunities such as collaboration agreements, equity offerings, or debt. Cost of sales for products is expected to increase in relation to product revenues as expensed inventories are depleted. The company plans to initiate monotherapy expansion cohorts for VS-7375 in advanced PDAC and NSCLC, subject to Phase 1 monotherapy dose escalation results, and to initiate VS-7375 dose escalation cohorts in combination with other agents for CRC, PDAC, and NSCLC in Q4 2025, with subsequent combination expansion cohorts planned. The company expects its current cash, cash equivalents, and investments to provide a cash runway into the second half of 2026.

Management Comments

• "In the second quarter of 2025, AVMAPKI FAKZYNJA CO-PACK became the first-ever treatment approved by the FDA specifically for use in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, and we are off to a strong start with the launch of this innovative combination therapy."
• "In the quarter, we also made significant progress across our pipeline programs with the first patient dosed in the U.S. Phase 1/2a trial for VS-7375, our potential best-in-class KRAS G12D (ON/OFF) inhibitor, and with positive updated data from our RAMP 205 trial in the front-line setting of metastatic pancreatic cancer."
• "Our focus for the second half of the year is to continue to build on the positive launch momentum, continue to advance RAMP 205 and RAMP 301 clinical trials, and enroll patients in both the VS-7375 monotherapy and combination cohorts to unlock new opportunities with our RAS/MAPK-pathway focused portfolio."

Industry Context

Verastem operates in the highly competitive and innovation-driven biopharmaceutical sector, specifically focusing on oncology, particularly RAS/MAPK pathway-driven cancers. The FDA approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated LGSOC is a significant event, as it addresses a specific, previously unmet medical need, positioning the company as a leader in this niche. The development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, places Verastem in the evolving landscape of KRAS-targeted therapies, a field that has seen increased interest following the success of KRAS G12C inhibitors. The company's strategy of pursuing combination therapies (e.g., avutometinib + defactinib, and triplet combinations) aligns with broader industry trends aimed at overcoming drug resistance and enhancing treatment efficacy in complex cancer types like pancreatic cancer, which remains an area of high unmet medical need. Collaborations with entities like GenFleet Therapeutics and Amgen reflect a common industry approach to share development risks and leverage specialized expertise.

Comparison to Industry Standards

• The confirmed Objective Response Rate (ORR) of 83% (10/12 patients) in the RAMP 205 Phase 1/2 trial for first-line metastatic PDAC is notably high for this indication, where historical ORRs for standard chemotherapy regimens (e.g., gemcitabine/nab-paclitaxel) typically range from 20-30%. This suggests a potentially superior efficacy profile for the avutometinib/defactinib combination in this difficult-to-treat cancer.
• The reported ORRs for VS-7375 (GFH375) from GenFleet's Phase 1 study in China (52% in PDAC and 42% in NSCLC, with 75% of patients having received 2 prior lines of therapy) are strong for a KRAS G12D inhibitor, especially in a heavily pre-treated population. While direct comparative data to other KRAS G12D inhibitors in development are not provided, these figures suggest a competitive profile in a challenging therapeutic area.

Stakeholder Impact

• Shareholders face potential for value creation from the new product launch and pipeline progress, but also dilution risk from past and potential future capital raises, alongside significant financial losses and a going concern warning.
• Patients with KRAS-mutated recurrent LGSOC now have a new FDA-approved treatment option (AVMAPKI FAKZYNJA CO-PACK). Ongoing clinical trials for VS-7375, RAMP 203, RAMP 205, and RAMP 301 offer hope for future treatment advancements in various cancer types.
• Employees are impacted by continued operations and R&D efforts, with stock-based compensation being a notable component of their remuneration.
• Creditors have secured obligations under the new Note Purchase Agreement, following the repayment of the previous Loan Agreement.
• Suppliers, Contract Research Organizations (CROs), and Contract Manufacturing Organizations (CMOs) will continue to be engaged for ongoing R&D and manufacturing activities.

Next Steps

• Continue to build on the positive launch momentum for AVMAPKI FAKZYNJA CO-PACK.
• Continue to advance RAMP 205 and RAMP 301 clinical trials.
• Enroll patients in both VS-7375 monotherapy and combination cohorts.
• Report outcome of the IDMC's sample-size re-estimation recommendation for RAMP 301 in Q4 2025.
• Report initial data from the RAMP 201J Phase 2 clinical trial in Japan in Q4 2025.
• Continue to advance the regulatory pathway for AVMAPKI FAKZYNJA CO-PACK in Japan and Europe.
• Report a preliminary update on the VS-7375 Phase 1 monotherapy dose escalation in Q4 2025.
• Subject to the results of the Phase 1 monotherapy dose escalation, initiate VS-7375 monotherapy expansion cohorts in both advanced PDAC and NSCLC.
• Initiate VS-7375 dose escalation cohorts in combination with cetuximab, chemotherapy, and chemotherapy with checkpoint-inhibitor for CRC, PDAC, and NSCLC, respectively, in Q4 2025.
• Subject to the results of the Phase 1 dose escalation combinations cohorts with VS-7375, initiate a combination expansion cohort in CRC, PDAC, and NSCLC.
• Complete enrollment in the RAMP 205 expansion cohort in Q3 2025.
• Report an interim update on the safety and efficacy results in RAMP 203 from both the doublet and triplet combinations in Q4 2025.
• The NCCN Committee for Ovarian Cancer will hold its annual meeting in October 2025 to review the company's submission for the inclusion of the KRAS wild-type population in the NCCN Guidelines.

Key Dates

Recommendation

The FDA approval and initial sales of AVMAPKI FAKZYNJA CO-PACK are significant positive catalysts, establishing a revenue stream. Promising early data from pipeline assets like VS-7375 and RAMP 205 also provide future upside potential. However, the substantial increase in net loss, the explicit 'going concern' warning, and the continued reliance on external financing or future milestones introduce considerable financial risk. The company's cash runway into H2 2026 provides some near-term stability, but the long-term financial viability remains contingent on successful commercialization and further pipeline advancements. For a seasoned investor, the current situation presents a balanced risk-reward profile, warranting a 'Hold' as they monitor the commercial ramp-up and confirmatory trial results.

Keywords

Biopharmaceutical, Oncology, RAS/MAPK pathway, AVMAPKI FAKZYNJA CO-PACK, Avutometinib, Defactinib, KRAS-mutated, Low-grade serous ovarian cancer, LGSOC, VS-7375, KRAS G12D inhibitor, Pancreatic cancer, PDAC, Non-small cell lung cancer, NSCLC, Clinical trials, FDA approval, Drug development, Biotech, Pharmaceuticals